Time to Change the Treatment Paradigms in Anaplastic Thyroid Carcinoma

April 17, 2012

In rare diseases, the “magic” lies in close collaboration between individual investigators at academic institutions, the pharmaceutical industry, and funding institutions such as the National Cancer Institute.

Anaplastic thyroid cancer (ATC) is a rare cancer and one of the least common thyroid cancers. It is also the most aggressive and lethal of the thyroid cancers. Management with an eye towards palliative care and symptom control is an integral component of treatment because the disease is almost uniformly fatal, with death frequently associated with airway obstruction (disease-specific mortality is close to 100%). Thus, the main goal of treatment today is to prevent death from uncontrolled disease in the neck and subsequent suffocation. As meticulously presented by Drs. Burnison and Lim, better locoregional control has improved median survival in ATC. However, our future focus should not be just on the primary tumor but on the integration of treatment modalities, new biological agents, circulating tumor cells, and the tumor microenvironment and vasculature, as these may directly target the cancer and decrease the risk of distant metastases.

Unfortunately, although they are much needed, randomized clinical trials in ATC are almost nonexistent. The major obstacles for any clinical trials in ATC are the rarity of the disease and the rapidity of tumor growth and morbidity, which make patient recruitment problematic and slow. Long trial completion times increase the risk that additional new therapies will be identified before trial completion or that costs will increase unacceptably, as a product of the number of centers and the amount of time that has elapsed. In addition, studies that include numerous sites, over large regions and with low site accrual, face challenges involving consistent data collection, logistics, genetic differences in populations, differences in disease etiology, access to technology, and differences in technical standards (intensity-modulated radiation therapy [IMRT], biomarkers), as well as data dilution. As a consequence of these factors, there is a notable absence of a modern standard of care; thus, current evidence often comes from scattered, uncontrolled retrospective reviews and small-volume phase II studies. Although technology and the expansion of quality clinical research throughout the world have improved access and operations for clinical trials, we have to admit that there is no magic short-term solution for this orphan disease.

As the authors have noted, definitive local therapy is an essential component of the initial treatment of ATC. However, when either surgery or radiation is used as a single treatment modality, high rates of locoregional and distant recurrence are seen. Surgical resection followed by external beam radiotherapy (EBRT) for ATC was able to lower cause-specific mortality.[1] As with other malignancies, in order to improve outcomes in ATC, chemotherapy has been integrated into multimodality approaches.[2,3] In other malignancies, adjuvant chemotherapy not only reduces tumor volume but also makes the tumor resectable, with the additional advantage of preventing distant metastasis. Unfortunately, few agents are active in ATC. Nonetheless, the more modest outcomes in ATC have motivated clinical practice. The introduction of concurrent radiation with doxorubicin as a definitive treatment or following debulking surgery for ATC has resulted in improvements in local control and median survival, changing the natural history from local and regional recurrence to distant metastases as a leading cause of death.[4,5] In other malignant diseases-and anecdotally in ATC-with difficult and locally aggressive disease, much effort has been devoted to overcoming radioresistance by studying synergistic effects of different chemotherapy agents, combinations, and now targeted therapies (with the latter also given in combination with chemotherapy). In the case of ATC, this approach is supported by data demonstrating that paclitaxel given as single-agent chemotherapy in patients with ATC showed the highest response rate (50%) reported in a single phase II study. These results suggest that taxanes, which are also excellent radiosensitizers, could be among the most active agents for use in concurrent and combined therapies.[6] Two other studies have shown promising results with the combination of docetaxel and radiation. In one study, with a median follow-up of 21.5 months (range, 2–40 months), five out of six patients are alive. In a second trial, median survival was 40 months, with 60% alive at 2 years. Treatment was not without a significant symptomatic price; in both studies most patients were hospitalized for severe mucositis or infection.[7,8]

The incorporation of chemotherapy and targeted therapy early in treatment may also reduce rates of distant failure. Biological agents that are under development in animal models or clinical trials create an exciting new horizon for ATC. Combretastatin-A4 phosphate (CA4P) is an example. In contrast to other anti–vascular endothelial growth factor (VEGF) agents that block the formation of new vessels in tumors, CA4P stops blood flow through already existing abnormal blood vessels, which are markedly increased in ATC. CA4P was used with carboplatin-paclitaxel against ATC in a nude mouse xenograft model.[9] The combination showed significant activity, and on the basis of these findings, the triplet combination of paclitaxel and carboplatin with or without CA4P was evaluated in a phase II/III trial-the FACT (Fosbretabulin in Anaplastic Cancer of the Thyroid) trial.[10] Unfortunately, the study was closed prematurely due to slow accrual (80 patients) and inadequate funding. When the results were presented at the American Society of Clinical Oncology (ASCO) 2011 conference, the rate of patients surviving 1 year was higher in the experimental triplet arm than in the comparator arm (pacitaxel + carboplatin)-24% vs 9%-suggesting a survival benefit for CA4P. Compounds that target tumor vasculature or collapse tumor vasculature are a matter of great clinical interest and investigation. Currently, crolibulin (NCT01240590), a combretastatin derivative, and also combinations of bevacizumab (Avastin) and doxorubicin (NCT00804830), are being studied in clinical trials.

With regard to new biological agents, histone deacetylase inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, farnesyl-transferase inhibitors, and PI3K inhibitors have been tested in preclinical models or clinical trials, with encouraging activity. A few will be studied in ATC in small clinical trials. It is hoped that the results from these preclinical and clinical studies will increase the limited therapeutic options for this deadly disease.[12-18]

In rare diseases, evidence will be of lesser quality than that available in the more common cancers; because of the difficulty of collecting adequate numbers of patients, it will come from small trials and frequently from retrospective studies. To improve the quality of studies, new research should be conducted with high methodological standards and good data collection, and it should address specific questions. It is very difficult, in single-institution studies, to detect incremental improvement in rare and unresponsive diseases such as ATC. The long-term goals would be to identify “home runs” through new biological agents such as the PI3K, B-raf, or Akt inhibitors that address the fundamental biology of the tumor, and in the interim to work in a multidisciplinary setting. In rare diseases, the “magic” lies in close collaboration between individual investigators at academic institutions, the pharmaceutical industry, and funding institutions such as the National Cancer Institute.

Financial Disclosure:Dr. Posner serves as a consultant for Oxigene, Eisei, GlaxoSmithKline, Novartis, and CEL-SCI. Dr. Misiukiewicz has no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

References:

References

1. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000;11:1083-9.

2. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848-53.

3. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002;83:21-38.

4. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60:2372-5.

5. Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg. 2004;93:272-7.

6. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10:587-94.

7. Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95:E54.

8. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21:25-30.

9. Yeung SC, She M, Yang H, et al. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007;92:2902-9.

10. ClinicalTrials.gov Identifier: NCT00507429.

11. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol. 2011;29(suppl):abstr 5502.

12. Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope. 2007;117:674-9.

13. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol. 2006;191:465-72.

14. Ha HT, Lee JS, Urba S, et al. Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC) J Clin Oncol. 2009;27(suppl 15):abstr 6057.

15. Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab. 2007;92:1938-42.

16. Yeung SC, Xu G, Pan J, et al. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res. 2000;60:650-6.

17. Juric D, Baselga J. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol. 2012;30:765-6.

18. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-70.